# B-FREE Chronic Babesiosis Study

> **NCT06656351** · PHASE2 · RECRUITING · sponsor: **60 Degrees Pharmaceuticals LLC** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Babesiosis

## Interventions

- **DRUG:** Tafenoquine 100mg

## Key facts

- **NCT ID:** NCT06656351
- **Lead sponsor:** 60 Degrees Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-18
- **Primary completion:** 2027-02
- **Final completion:** 2027-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06656351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06656351, "B-FREE Chronic Babesiosis Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06656351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*